NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Niagen Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.50+0.01 (+0.40%)
Close on Oct 19, 2026
- Market cap
- $206.26M
- P/E (TTM)
- 13.9
- Dividend yield
- –
Niagen Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Market Cap | $197.82M | $164.85M |
| Enterprise Value | $131.08M | $87.06M |
| PE Ratio | 13.89 | 19.63 |
| PS Ratio | 1.53 | 3.60 |
| PB Ratio | 2.40 | 2.03 |
| P/TBV Ratio | 2.56 | 2.31 |
| P/OCF Ratio | 33.25 | 13.32 |
Enterprise value
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| EV / Sales | 1.02 | 2.43 |
| EV / EBITDA | 12.37 | 14.69 |
| EV / EBIT | 12.37 | 18.47 |
Income (trailing twelve months)
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Revenue | $129.08M | $57.94M |
| Gross Profit | $82.92M | $90.47M |
| Operating Income | $10.60M | -$21.44M |
| Pretax Income | $17.03M | -$14.45M |
| Net Income | $15.99M | -$22.46M |
| EBITDA | $10.60M | -$16.91M |
| EPS (Diluted) | $0.18 | -$0.83 |
Margins
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Gross Margin | 64.2% | 52.3% |
| Operating Margin | 8.21% | -44.5% |
| Pretax Margin | 13.2% | -13.0% |
| Profit Margin | 12.4% | -39.2% |
| EBITDA Margin | 8.21% | -31.3% |
Returns
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | 21.8% | -53.1% |
| Return on Assets (ROA) | 16.1% | -41.0% |
| Return on Invested Capital (ROIC) | 102.0% | -32.0% |
| Return on Capital Employed (ROCE) | 11.6% | -37.8% |
Growth
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.0% | 6.01% |
| Net Income Growth (YoY) | -9.80% | -37.7% |
| EPS Growth (YoY) | -14.3% | -29.2% |
| Revenue Growth (3Y CAGR) | 21.6% | 2.25% |
| Revenue Growth (5Y CAGR) | 16.9% | 6.42% |
Balance sheet
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $66.74M | $62.42M |
| Net Cash (Debt) | $66.74M | $15.68M |
| Net Cash Per Share | $0.84 | $0.66 |
| Equity (Book Value) | $82.53M | $48.79M |
| Book Value Per Share | $1.04 | $1.36 |
| Tangible Book Value | $77.22M | $23.06M |
| Working Capital | $82.74M | $75.77M |
Financial position
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Current Ratio | 6.50 | 3.30 |
| Quick Ratio | 5.00 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | $5.95M | -$12.35M |
Efficiency
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 1.30 | 0.38 |
| Inventory Turnover | 2.63 | 2.67 |
| Revenue Per Employee | $1.10M | $398.96K |
| Profits Per Employee | $136.68K | -$703.34K |
| Employee Count | 117 | 74 |
Dividends and yields
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Earnings Yield | 8.08% | -22.7% |
Shares
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 79,126,000 | 58,179,650 |
| Shares Change (YoY) | 2.93% | 11.1% |
| Shares Change (QoQ) | -0.69% | 0.54% |
| Float | 75,110,500 | 49,173,100 |
| Shares Held by Insiders | 5.07% | 11.6% |
| Shares Held by Institutions | 40.4% | 59.4% |
Taxes
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Income Tax | $1.04M | $91.50K |
| Effective Tax Rate | 6.09% | 20.6% |
Scores
| Measure | Niagen Bioscience | Industry median |
|---|---|---|
| Graham Number | $2.06 | $17.36 |
| Graham Upside | -17.8% | -43.6% |
| Altman Z-Score | 5.34 | -0.24 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Niagen Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.